Kevin A. O’Connor Ph.D.

Kevin A. O’Connor, Intellectual Property & Technology Transactions attorney, Neal Gerber law firm
Organization Profile
(312) 269-5358
Professional Biography

Kevin O’Connor has represented clients in all aspects of patent law, including patent prosecution, strategic management of patent portfolios, due diligence investigations for acquisitions and mergers, freedom to operate investigations, interference practice and litigation. Kevin’s work has encompassed a broad spectrum of technologies in the biotechnological, pharmaceutical and medical device arts, including therapeutic antibodies and peptides, small molecules, and nucleic acids such as silencing RNAs and their use in treating conditions such as autoimmune diseases, pain, cancer and neurological diseases; stem cells and the cell therapy field; nutraceuticals; coronary stent systems; hematology analyzers and controls; and diabetes management devices.

Kevin donates his time and energy to advocacy for blood cancer research and serves on the Leadership Board of the Illinois Chapter of the Leukemia & Lymphoma Society.

Kevin received his Ph.D. in Neuroscience from the University of Colorado. His studies focused on interactions between the central nervous system and the immune system, with emphasis on the role of immune cell products, particularly cytokines, in central nervous system function. After finishing his graduate work, Kevin joined the Molecular and Cellular Pathobiology Program at Children’s Memorial Research Center in Chicago to study the pathophysiology of a pediatric inflammatory disease. As an undergraduate at Creighton University, he was awarded a fellowship to study pharmacological and environmental regulation of serotonin receptors in the brain. His laboratory work involved utilization of various molecular biology techniques, immunoassays, and in vitro cell culture techniques.

  • More Legal and Business Bylines From Kevin A. O’Connor Ph.D.


NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins


Sign Up for e-NewsBulletins